Taking A Look Behind Hedge Funds Once dismissed as

New Post Public Reply Private Reply Replies (0) Message Board
NITE


Taking A Look Behind Hedge Funds
Once dismissed as secretive, risky and only for the well-heeled, hedge funds represent a growth industry. They can promise higher-than-average market returns in a downtrodden market, but despite the allure of these alternative investment vehicles, investors should think twice before taking the hedge fund plunge.



What Are Hedge Funds?
Hedge funds are privately offered investments that use a variety of non-traditional strategies to try to offset risk, an approach called - you guessed it - hedging.

One such technique is short selling. Hedge fund managers identify a stock in which price is likely to decline, borrow shares from someone else who owns them, sell the shares and then make money by later replacing the borrowed shares with others bought at a much lower price; buying at this lower price is possible only if the share price actually falls.

Hedge fund managers also invest in derivatives, options, futures and other exotic or sophisticated securities. Generally, hedge funds operate as limited partnerships or limited liability companies and they rarely have more than 500 investors each. (For more read Getting To Know Hedge-Like Mutual Funds.)

Arguments for Hedge Funds
Some hedge fund managers say these funds are the key to consistent returns, even in downtrodden markets. Traditional mutual funds generally rely on the stock market to go up; managers buy a stock because they believe its price will increase. For hedge funds, at least in principle, it makes no difference whether the market goes up or down.

While mutual fund managers typically try to outperform a particular benchmark, such as the S&P 500, hedge fund managers disregard benchmarks. They aim instead for absolute returns; in most cases a return of a certain percentage, year in and year out, regardless of how well the market does.

The argument goes like this: since hedge funds don't track the market, they, at the very least, protect the investor's portfolio. At the same time, as several successful hedge funds have demonstrated, they can also generate very high returns. The multibillion dollar Quantum Fund managed by the legendary George Soros, for instance, boasted compound annual returns exceeding 30% for more than a decade. (You can read more about George Soros in the Greatest Investors tutorial.)

Why Investors Should Think Again
The arguments are certainly compelling, but be warned. For starters, there is a big catch: most hedge funds require a minimum investment of $1 million. Granted, investors can now choose from a growing number of "lite" hedge funds, which have more affordable minimum investments. The lowest ones, however, start at $100,000. For most investors, that is hardly spare change. Lack of liquidity is another drawback. Investments may be locked up for as long as five years.

What about the risk? High-profile collapses are reminders that hedge funds are not immune to risk. Led by Wall Street trader John Meriwether and a team of finance wizards and Ph.D.s, Long Term Capital Management imploded in the late 1990s. It nearly sank the global financial system and had to be bailed out by Wall Street's biggest banks. In 2000, George Soros shut down his Quantum Fund after sustaining stupendous losses. (For more on this, read Massive Hedge Fund Failures.)
For nearly every hedge fund that opens its doors to investors, another is forced to liquidate after poor performance. While some funds have delivered spectacular gains, many others have performed so poorly that average hedge fund returns have fallen below market levels.

A Closer Look at the Risks
A study by Yale and NYU Stern economists suggested that during that six-year period, the average annual return for offshore hedge funds was 13.6%, whereas the average annual gain for the S&P 500 was 16.5%. Even worse, the rate of closure for funds rose to more than 20% per year, so choosing a long-term hedge fund is trickier than even choosing a stock investment.

Management inexperience may explain the high rate of attrition. Remember, there are thousands of hedge funds in the U.S., a dramatic increase from 880 in 1991. This means that many of the managers are brand new to the hedge fund game. Many have come from traditional mutual funds and are not experienced with selling "short" or with the other sophisticated securities instruments at their disposal. They must learn by trial and error. Veterans are quick to point out that successful shorting involves a long learning curve, which is also difficult to execute. Short selling, moreover, typically relies heavily on leverage, making the manager's job even tougher.

Even investors comfortable with risk should still be aware of other drawbacks. For one, hedge fund fees are much higher than those of traditional mutual funds. Hedge funds typically charge 1 to 2% of assets plus 20% of profits. Given the profits that managers take, hedge funds often don't deliver to investors the promise of market-beating performance.

Another sticking point is poor transparency. The Securities and Exchange Commission doesn't dictate the same strict rules for hedge funds that it does for traditional mutual funds. Managers can make up the portfolios as they please, and there are no rules for providing information about holdings and performance. Although hedge funds are subject to anti-fraud standards and require audits, you should not assume that managers are more forthcoming than they need to be. This lack of transparency can make it hard for investors to distinguish risky funds from tame ones.
Finally, hedge funds can bring a big tax bite. Because managers buy and sell so frequently, investors incur high capital gains, which are normally taxed at the ordinary income tax rate.

The Bottom Line
The logic behind hedge fund investing is compelling, but before piling in investors should take their time and do the necessary due diligence on the fund and its managers. Finally, they should remember to weigh the risks. It might be wise for them to consider if they aren't better off with an index fund.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Coke Florida's Commitment to Coastal Cleanliness Shines Bright

Updated Category News Views 141

Coke Florida's Volunteer Contributions for Coastal Cleanup Day Coca-Cola Beverages Florida, LLC (Coke Florida) was excited to take part in the worldwide celebration of International Coastal Cleanup (ICC) Day. This initiative, which focuses on sustainability and building community resilience, encouraged employees across the company's vast market to unite for a meaningful...

Continue Reading
LifeMD's Growth Momentum: Strong Earnings and Legal Support

Updated Category News Views 96

LifeMD Maintains Buy Rating Amid Positive Developments BTIG has reaffirmed its support for LifeMD Inc (NASDAQ: LFMD) by maintaining a Buy rating and a price target of $12.00 for the company’s stock. This endorsement comes at a pivotal time as the company experiences recent developments in the ongoing legal proceedings regarding tirzepatide, a drug used for treating type...

Continue Reading
Innovative Electric Heating Pad Adapter Set to Transform Comfort

Updated Category News Views 120

Innovative Heating Pad Adapter for Vehicles Inventors continuously strive to enhance daily experiences, and one such innovation is set to revolutionize comfort during travel. An inventor, inspired by the need for warmth while driving, developed the RIDE ALONG PRONG PLUG IN, a unique electric heating pad adapter accessible through a vehicle's cigarette lighter socket....

Continue Reading
Hang Feng Capital's Innovations Shine at Asia’s FinTech Hub

Updated Category News Views 158

Hang Feng Capital Excels at Hong Kong FinTech Week Recently, a remarkable event unfolded in the heart of Asia's financial landscape as Hang Feng Capital showcased its innovations during Hong Kong FinTech Week. Co-hosted by the local government and InvestHK, this pivotal event brought together over 700 exhibitors, 800 speakers, and an impressive crowd of 37,000 attendees...

Continue Reading
Autoliv Inc. Adjusts Revenue Forecast Amid Changing Market

Updated Category News Views 60

Autoliv Inc. got slapped with a serious reality check back in 2024 when JPMorgan revised its price target to $119, up just a hair from $117. You could feel the desks twitching as analysts dove into the automotive safety systems market, flagging Autoliv’s shaky standing amidst some forecasted storms brewing on the horizon. Global light vehicle production was supposed to...

Continue Reading